BCEL:NSD-Atreca, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 15.50

Change

-0.04 (-0.26)%

Market Cap

USD 0.57B

Volume

0.19M

Average Target Price

USD 29.00 (+87.10%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a strategic research collaboration with Merck Sharp & Dohme Corp. to identify the antigenic targets of select antibodies discovered with potential utility in oncology. Atreca, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-11.73 (-7.68%)

USD60.44B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+2.55 (+1.12%)

USD59.22B 22.32 17.39
REGN Regeneron Pharmaceuticals, Inc

-1.96 (-0.38%)

USD55.06B 18.91 14.53
SGEN Seagen Inc

+7.10 (+4.17%)

USD30.48B 64.32 62.62
BNTX BioNTech SE

-10.23 (-8.23%)

USD29.92B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+0.04 (+0.03%)

USD26.72B 28.34 26.92
RPRX Royalty Pharma plc

+0.18 (+0.42%)

USD26.64B 22.60 9.74
GMAB Genmab A/S

-0.37 (-0.96%)

USD25.29B 26.59 2.61
BGNE BeiGene, Ltd

-9.20 (-3.60%)

USD21.65B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BCEL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.19% 47% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.19% 47% F 47% F
Trailing 12 Months  
Capital Gain 16.19% 52% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.19% 52% F 62% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.26% N/A N/A 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.26% N/A N/A 34% F
Risk Return Profile  
Volatility (Standard Deviation) 9.76% N/A N/A 89% B+
Risk Adjusted Return 2.65% N/A N/A 34% F
Market Capitalization 0.57B 65% D 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 4.44 58% F 86% B
Price/Book Ratio 2.21 76% C 53% F
Price / Cash Flow Ratio -9.74 62% D- 79% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -35.79% 73% C 27% F
Return on Invested Capital -47.75% 64% D 20% F
Return on Assets -22.19% 61% D- 17% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 19.55 7% F 3% F
Short Percent 12.68% 24% F 16% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector